Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$19.43 USD
-0.19 (-0.97%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $19.44 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRDN 19.43 -0.19(-0.97%)
Will VRDN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRDN
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
VRDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Other News for VRDN
Leerink Partners Keeps Their Buy Rating on Viridian Therapeutics (VRDN)
VRDN Crossed Above 20 Day Moving Average on September 18
Is VRDN likely to continue lower? 20 Day Moving Average Resistance shows up after sinking 0.21%
Non-ADX 1,2,3,4 Bullish appears for VRDN after 3.61% move
VRDN Fell Below 20 Day Moving Average on September 15